* Dare Bioscience Inc reported a quarterly adjusted loss of 88 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-1.20. The mean expectation of four analysts for the quarter was for breakeven results per share. Wall Street expected results to range from -84 cents to $1.92 per share.
* Revenue was $22.44 million; analysts expected $5.89 million.
* Dare Bioscience Inc's reported EPS for the quarter was $1.52.
* The company reported quarterly net income of $12.91 million.
* Dare Bioscience Inc shares had fallen by 15.9% this quarter and lost 8.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 100% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Dare Bioscience Inc is $48.00 This summary was machine generated from LSEG data August 13 at 12:51 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 0.00 -0.88 Missed
Mar. 31 2024 -0.72 -0.84 Missed
Dec. 31 2023 -1.18 -0.72 Beat
Sep. 30 2023 -1.18 -1.08 Beat
Comments